Citadel & Centurion are multi-center studies that are evaluating the use of TYRX’s AIGISRx Antibacterial Envelope in patients who are at high risk for cardiovascular implantable electronic devices infection. High-risk patients are those whose current CIED is being replaced with an implantable cardioverter-defibrillator or a cardiac resynchronization therapy device accompanied by the AIGISRx.
The AIGISRx Antibacterial Envelope is a mesh device that holds a pacemaker or implantable cardioverter-defibrillator in place and is coated with antibiotic agents to reduce infections.
More Articles on TYRX:
Study Reveals TYRX Antibacterial Envelope Helps Lower Infections From Cardiac Devices
TYRX Announces ICD-9 Code for AIGISRx Antibacterial Envelope
TYRX Launches New Patient Education Website
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
